Some of the most consistent indications for cannabis based medicine are Pain/inflammation, anxiety and sleep—a trifecta of challenges in the management of debilitating symptoms of persistent Lyme and associated diseases and Post Treatment Lyme Disease Syndrome (PTLDS).

There is no standard, approved treatment for this chronic condition. With the CDC estimating nearly 500,000 new Lyme cases each year, with up to 20% remaining chronic, this presents as a significant gap in public health.

Compelling anecdotes highlight the benefits experienced by patients who have integrated cannabis into their treatment plans, including pain relief, improved sleep, and enhanced well-being. In the absence of clinical trials, real-world evidence of the measurable efficacy of cannabis is useful to validate such anecdotes. This presentation will review in depth the largest known standardized, quantifiable real-world evidence data set, provided by Strainprint, measuring cannabis used for relief from symptoms of Lyme and associated diseases. Within the dataset strong correlations for targeted symptom relief are demonstrated. In particular the data supports mixed cannabinoid formulations providing greater efficacy at lower doses.

We will also discuss a study design, incorporating Strainprint data collection that would allow for further investigation of this treatment modality.

Learning Objectives:

• Be able to discuss the underrated prevalence and severity of persistent and post-treatment Lyme disease syndrome.
• Be able to discuss cannabinoid based treatment for the relief of common symptoms of PTLDS and persistent infection.